Compounds having the structure of formula I are provided. In formula I, R.sub.1 is H, OH, substituted or unsubstituted C.sub.1 to C.sub.3 alkyl, C.sub.1 to C.sub.3 perfluoroalkyl, or COR.sub.6; R.sub.6 is H, substituted or unsubstituted C.sub.1 to C.sub.4 alkyl, aryl, substituted or unsubstituted C.sub.1 to C.sub.4 alkoxy, substituted or unsubstituted C.sub.1 to C.sub.3 aminoalkyl; R.sub.2 and R.sub.3 are H, substituted or unsubstituted C.sub.1 to C.sub.6 alkyl, C.sub.1 to C.sub.6 perfluoroalkyl, substituted or unsubstituted C.sub.2 to C.sub.6 alkenyl, substituted or unsubstituted C.sub.2 to C.sub.6 alkynyl, substituted or unsubstituted C.sub.3 to C.sub.6 cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclic; or R.sub.2 and R.sub.3 are fused to form spirocyclic rings; R.sub.4 is NHR.sub.7, OR.sub.7, NHSO.sub.2R.sub.7, or OSO.sub.2R.sub.7; Q is O, S, NR.sub.8, or CR.sub.9R.sub.10; or a pharmaceutically acceptable salt, ester, or prodrug thereof. Such compounds are useful as progesterone receptor modulators and for treating progesterone receptor related conditions. ##STR00001##